TTIPF — Thiogenesis Therapeutics, Corp.
—
OTC ·
Unknown ·
Unknown ·
CIK 1877778 ·
Last close
$0.42
Market Cap
$21.77M
52W High
$0.45
52W Low
$0.41
ADV30
0
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -917,825 | -911,820 | 1,029,620 | 903,464 | 1,256,189 |
| Dec 2025 | 0 | — | -1,730,916 | -1,731,838 | 1,814,967 | 1,615,966 | 1,240,590 |
| Sep 2025 | 0 | — | -2,394,412 | -2,383,961 | 3,625,225 | 3,502,183 | 1,471,940 |
| Jun 2025 | 0 | — | -1,834,664 | -1,899,443 | 1,940,380 | 1,843,475 | 1,483,545 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-4,664,568
Investing CF
—
Financing CF
$4,065,510
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.13
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-19,977,999
Inventory
—
Receivables
$68,123
ST Investments
—
EBIT TTM
$-6,980,768
Pretax Income TTM
$-6,821,220
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -7,395,226 | -7,426,077 | 1,814,967 | 1,240,590 | — | -6,032,623 |
| Dec 2024 | 0 | -3,579,274 | -3,145,730 | 3,983,388 | 557,876 | — | -3,920,570 |
| Dec 2023 | 0 | -5,206,021 | -5,063,011 | 7,243,000 | 1,712,866 | — | -3,248,463 |
| Dec 2022 | 0 | -1,974,847 | -3,924,251 | 6,290,572 | 307,151 | — | -2,089,693 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GWH | ESS Tech, Inc. | $21.95M | $0.75 | — |
| IEGCF | Independence Gold Corp. | $21.56M | $0.08 | — |
| ADTI | Adapti, Inc. | $21.56M | $2.56 | — |
| IRVRF | Irving Resources Inc. | $21.51M | $0.22 | — |
| ESGH | ESG Inc. | $22.13M | $1.43 | — |
News headlines (Yahoo Finance, 1h cache)
Thiogenesis Receives FDA Rare Pediatric Disease Designation for TTI-0102 for the Treatment of Leigh Syndrome
2026-07-13 10:00 · Yahoo
Thiogenesis Appoints Dr. Gilad Aharon to Its Board of Directors
2026-06-17 12:00 · Yahoo
Thiogenesis Closes Oversubscribed Non-Brokered Private Placement for Gross Proceeds of C$9.07 Million
2026-06-03 10:00 · Yahoo
Thiogenesis Upsizes Non-Brokered Private Placement of Common Shares
2026-06-01 18:49 · Yahoo
Thiogenesis Announces Non-Brokered Private Placement
2026-05-11 13:00 · Yahoo
Thiogenesis Therapeutics to Present at 2026 Bloom Burton & Co. Healthcare Investor Conference
2026-04-16 13:00 · Yahoo
kneat.com Spotlights ARR Surge to CAD 74M, New Strategic Customers and AI Rollout at Conference
2026-04-07 20:02 · Yahoo
Presenting on Emerging Growth Conference 91 Day 1 on April 1; Register to live stream
2026-03-31 11:00 · Yahoo
Thiogenesis Therapeutics Announces Investigator-Initiated Study in Nephropathic Cystinosis and Provides Program Update
2026-02-02 14:00 · Yahoo
Thiogenesis Presents Phase 2 (EU) MELAS Data at Mitocon 2026
2026-01-23 14:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.